Australia - englanti - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - canine distemper virus - living; canine adenovirus type 2 - live (infectious hepatitis); canine parvovirus - live - misc. vaccines or anti sera - canine distemper virus - living vaccine-viral active 0.0 p; canine adenovirus type 2 - live (infectious hepatitis) vaccine-viral active 0.0 p; canine parvovirus - live vaccine-viral active 0.0 p - immunotherapy - dog | bitch | castrate | puppy - canine distemper | canine parvovirus | hepatitis :- infectious | vaccine | canine adenovirus type 1 | canine adenovirus type 2 | equine rotavirus | infectious canine hepatitis | parvovirus

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - strain cr 326f hepatitis a virus, inactivated 50 u - suspension for injection in pre-filled syringe - 25 u/0.5 millilitre(s) - hepatitis vaccines; hepatitis a, inactivated, whole virus

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - 20 mcg/ml - active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate phenoxyethanol sodium chloride thiomersal water for injection active: hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium hydroxide dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection - engerix-b is indicated for active immunization against hepatitis b virus infection.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

merck sharp & dohme ireland (human health) limited - strain cr 326f hepatitis a virus, inactivated 50 u - suspension for injection in pre-filled syringe - 50 u/1 millilitre(s) - hepatitis vaccines; hepatitis a, inactivated, whole virus

Malta - englanti - Medicines Authority

smithkline beecham limited - hepatitis a virus (inactivated) - suspension for injection - hepatitis a virus (inactivated) 1440 elisa unit/dose - vaccines

Israel - englanti - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - suspension for injection - hepatitis a virus antigen, inactivated 1440 e.l.u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - active immunisation against infections caused by hepatitis a virus.the vaccine is particularly indicated for those at increased risk of infection or transmission.

Malta - englanti - Medicines Authority

smithkline beecham limited - hepatitis a virus (inactivated) - suspension for injection - hepatitis a virus (inactivated) 720 elisa unit/dose - vaccines

Euroopan unioni - englanti - EMA (European Medicines Agency)

mcm vaccine b.v. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3, hepatitis b surface antigen produced in yeast cells, poliovirus (inactivated): type 1 (mahoney), type 2 (mef-1), type 3 (saukett) produced in vero cells/ haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vaccines - vaxelis (dtap-hb-ipv-hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and invasive diseases caused by haemophilus influenzae type b (hib). the use of vaxelis should be in accordance with official recommendations.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 160 mg/ml; hepatitis b immunoglobulin, quantity: 100 iu - injection, solution - excipient ingredients: glycine; water for injections; human immunoglobulin a - indications as at 8 august 2002 : hepatitis b immunoglobulin is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (<10iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive material or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin is also indicated for prophylaxis in infants born to hbsag-positive mothers. hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (<10iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) - solution for injection - 100 iu - active: hepatitis b immunoglobulin, human 160 mg/ml ((>= 98% )as human plasma proteins (exnz)) excipient: glycine water for injection - hepatitis b immunoglobulin-vf is indicated for post-exposure prophylaxis in persons who did not receive prior vaccination, or whose prior vaccination regimen is incomplete, or when the hepatitis b antibody level is inadequate (< 10 iu/l). post-exposure prophylaxis should be considered following percutaneous or permucosal exposure to hbsag-positive or suspected hbsag-positive material, for example, by needle stick, oral ingestion or sexual exposure. hepatitis b immunoglobulin-vf is also indicated for prophylaxis in infants born to hbsag-positive mothers.